RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Association between medicare and FDA policies and prior authorization requirements for buprenorphine products in Medicare part d plans
Mark, T. L., Parish, W., & Zarkin, G. A. (2019). Association between medicare and FDA policies and prior authorization requirements for buprenorphine products in Medicare part d plans. JAMA, 322(2), 166-167. https://doi.org/10.1001/jama.2019.6581
This study describes changes in the proportion of Medicare Part D plans requiring prior authorization for buprenorphine products before and after a 2017 FDA rquirement that the drug’s label emphasize the importance of drug treatment of opioid use disorder.
